Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement EINDHOVEN, The Netherlands, 11 March 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the appointment of clinical nephrology experts An De Vriese, MD, PhD and Haimanot […]
Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief Technology Officer. EINDHOVEN, The Netherlands, 7 January 2025 – Xeltis, a leading […]
Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXessTM, its restorative vascular access conduit EINDHOVEN, The Netherlands, 5 November 2024 – Xeltis, a leading developer of transformative implants that enable the natural […]
Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel EINDHOVEN, The Netherlands, 17 April 2024 – Xeltis, […]
Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of established products for CNS disorders, pain and vascular diseases Dusseldorf and Barcelona, July 12, 2022 – Neuraxpharm Group (“Neuraxpharm”) today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi. With […]
